Edimer Pharmaceuticals Presents Update On Phase 2 Clinical Trial Of EDI200 At International Gathering Of Ectodermal Dysplasia Patient Foundations
4/1/2014 7:57:49 AM
Edimer Pharmaceuticals, a biotechnology company focused on developing an innovative therapy for the rare genetic disorder, X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), today announced that Neil Kirby, Ph.D., President and Chief Executive Officer of Edimer, presented an update on the company’s lead compound, EDI200, to the International Ectodermal Dysplasia Network meeting in Milan, Italy.
Help employers find you! Check out all the jobs and post your resume.
comments powered by